(CercleFinance.com) – Hybrigenics announces that its subsidiary Stemcis, specialized in the treatment of adipose tissue and stem cells in the context of plastic and reconstructive surgeries, has received the clearance letter from the FDA (Food and Drug Administration) authorizing it to market its medical devices in the United States.
This authorization will enable the company to expand its market and consolidate its position as a pioneer in the market for single-use devices intended for the community of specialized surgeons.
‘Stemcis brings to the market an innovative offer to help surgeons, by facilitating their procedures, and to reduce the infections of patients treated with a sterile single-use system’, emphasizes Hybrigenics.